Imbrium Therapeutics Presents Results of a Phase 2 Study of Sunobinop at 33rd American Academy of Addiction Psychiatry Annual Meeting
Retrieved on:
Monday, December 12, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Mental Health, Clinical Trials, Crave, Doctor of Pharmacy, Sleep, Maintenance, Therapy, Interstitial, Physician, M.A, AAAP, Addiction psychiatry, Conditional sentence, Polysomnography, AUD, Central nervous system, Eileen Brooke, American Academy, PSG, Patient, Prevalence, Somnolence, Alcoholism, Architecture, FDA, Peripheral nervous system, Pain, CI, Wakefulness, Journal of Medicinal Chemistry, NOP, PACS, LSM, Safety, Gene–environment correlation, Preclinical development, Overactive bladder, Anxiety, American Academy of Addiction Psychiatry, Kolla, Pharmaceutical industry, Mare Imbrium, Insomnia
The data were presented in a poster presentation (#76) at the 33rd Annual Meeting and Scientific Symposium of the American Academy of Addiction Psychiatry (AAAP).
Key Points:
- The data were presented in a poster presentation (#76) at the 33rd Annual Meeting and Scientific Symposium of the American Academy of Addiction Psychiatry (AAAP).
- Sunobinop is an internally discovered oral compound being evaluated as a potential treatment for multiple disorders including insomnia during recovery from AUD.
- The Phase 2 randomized, double-blind, multi-center, placebo-controlled, parallel-group clinical study enrolled 114 people experiencing insomnia during recovery from AUD.
- Imbrium is a clinical-stage biopharmaceutical company dedicated to advancing medical science through the development of important new pharmacologic and biologic therapeutics.